×

Avanir up on Alzheimer's trial

1:03 PM ET Mon, 15 Sept 2014

Avanir Pharma is up more than 60 percent, after the company said its drug was more effective in reducing agitation associated with Alzheimer's, compared with a placebo. CNBC's Meg Tirrell speaks to the company's CEO Keith Katkin.